Together is a new resource for anyone affected by pediatric cancer - patients and their parents, family members, and friends.Learn More
Tisagenlecleucel is a type of medicine called CAR T-Cell immunotherapy. This therapy works by engineering T cells to have special receptors called chimeric antigen receptors (CARs). These receptors help T cells to recognize and attack cancer cells.
A serious condition called cytokine release syndrome (CRS) can occur after receiving this therapy. This usually occurs within the first 1-2 weeks of therapy. Patients will be monitored for CRS during the infusion and for at least 4 weeks after treatment. A medicine called tocilizumab may be given if CRS develops after receiving CART cell therapy.
Patients will have regular blood draws to check blood counts and immunoglobulin levels.
Given as a liquid into a vein by IV
Cytokine release syndrome - symptoms can include:
Neurologic effects - symptoms can include:
Not all patients who take tisagenlecleucel will experience these side effects. Common side effects are in bold, but there may be others. Please report all suspected side effects to your doctor or pharmacist.
Some patients may experience long-term or late effects of treatment that may continue or develop months or years after treatment ends. Possible late effects due to tisagenlecleucel include:
Be sure to discuss these and other recommendations with your doctor or pharmacist.